Obstacles to Growth at Sanofi

Current fundamentals at Sanofi (SNY-$51.81) look dismal. Total revenue declined 2.8% to $9.36 billion (EURO 8.06 billion). Although quarterly sales missed consensus estimate of EURO 8.3 billion, double-digit gains from its rare-diseases division Genzyme (purchased for $20.1 billion in 2011), diabetes segment (driven by insulin Lantus), and emerging markets (like China in the Far East and Brazil in South America) saved the company from an even bigger hit to sales.

Additionally, blockbuster status (defined as annual peak sales of at least $1.0 billion) of recently approved medicines - like the colorectal cancer drug Zaltrap and multiple sclerosis therapy Aubagio - is far from certainty.

Read more at YCharts: Ugly Truth About Sanofi Stock

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.